{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:10:42Z","timestamp":1780416642619,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009228","name":"Region \u00d6rebro l\u00e4n","doi-asserted-by":"publisher","award":["OLL- 973562"],"award-info":[{"award-number":["OLL- 973562"]}],"id":[{"id":"10.13039\/501100009228","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009228","name":"Region \u00d6rebro l\u00e4n","doi-asserted-by":"publisher","award":["OLL-990588"],"award-info":[{"award-number":["OLL-990588"]}],"id":[{"id":"10.13039\/501100009228","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.106992","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T17:16:53Z","timestamp":1768324613000},"page":"106992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunoglobulin-G dynamics and relation to antibiotic prescriptions in multiple sclerosis patients treated with rituximab: a real-world cohort"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9259-2471","authenticated-orcid":false,"given":"Niclas","family":"Lange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Tina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Hultgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gunnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2026.106992_bib0001","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ana.26914","article-title":"Real-world healthcare cost savings and reduced relapse rate with off-label Rituximab versus disease-modifying treatments approved for relapsing\u2013Remitting multiple sclerosis: a nationwide cost-effectiveness study","volume":"95","author":"Alping","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.106992_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1548379","article-title":"Stability of cytokine and immunoglobulin concentrations in the general population: prepandemic basal concentrations and intraindividual changes until the COVID-19 pandemic","volume":"13","author":"Gasull","year":"2025","journal-title":"Front. Public Health"},{"issue":"7","key":"10.1016\/j.msard.2026.106992_bib0003","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2026.106992_bib0004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.biomag.2013.09.002","article-title":"The concentration of total serum IgG and IgM in sera of healthy individuals varies at different age intervals","volume":"3","author":"Jazayeri","year":"2013","journal-title":"Biomed. Aging Pathol."},{"issue":"3","key":"10.1016\/j.msard.2026.106992_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, Rituximab, hypogammaglobulinemia, and risk of infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol. Neuroimmunol Neuroinflammation"},{"issue":"2","key":"10.1016\/j.msard.2026.106992_bib0006","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, Rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMa Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.106992_bib0007","article-title":"Infectious complications as a predictor of mortality in patients with non-hodgkin lymphoma receiving Rituximab- containing chemotherapy","volume":"71","author":"Meza-Meneses","year":"2019","journal-title":"Rev. Investig. Cl\u00ednica."},{"issue":"2","key":"10.1016\/j.msard.2026.106992_bib0008","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2249.2010.04206.x","article-title":"Reference values for B cell subpopulations from infancy to adulthood","volume":"162","author":"Morbach","year":"2010","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2026.106992_bib0009","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1212\/NXI.0000000000001115","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with Rituximab","volume":"9","author":"Perriguey","year":"2022","journal-title":"Neurol. Neuroimmunol Neuroinflammation"},{"issue":"4","key":"10.1016\/j.msard.2026.106992_bib0010","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ana.27012","article-title":"COMBAT-MS: a population-based observational cohort study addressing the benefit-risk balance of multiple sclerosis therapies compared with Rituximab","volume":"96","author":"Piehl","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.106992_bib0011","series-title":"Swedres-Svarm 2020: Sales of Antibiotics and Occurrence of Antibiotic Resistance in Sweden","year":"2021"},{"issue":"8","key":"10.1016\/j.msard.2026.106992_bib0012","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40263-021-00810-3","article-title":"Predicting infection risk in multiple sclerosis patients treated with Ocrelizumab: a retrospective cohort study","volume":"35","author":"Seery","year":"2021","journal-title":"CNS. Drugs"},{"issue":"8","key":"10.1016\/j.msard.2026.106992_bib0013","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial","volume":"21","author":"Svenningsson","year":"2022","journal-title":"Lancet Neurol."},{"issue":"7_Supplement_1","key":"10.1016\/j.msard.2026.106992_bib0014","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1212\/WNL.0000000000208733","article-title":"Risk of hypogammaglobulinemia and infections associated with Rituximab therapy in patients with Multiple sclerosis: a systematic review and meta-analysis (P8-1.013)","volume":"104","author":"Talah","year":"2025","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2026.106992_bib0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-021-01037-3","article-title":"Long-term safety of Rituximab (Risks of Viral and Opportunistic Infections)","volume":"23","author":"Varley","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"issue":"9","key":"10.1016\/j.msard.2026.106992_bib0016","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"Vollenhoven","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2026.106992_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878340","article-title":"Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course","volume":"12","author":"Zoehner","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:50:44Z","timestamp":1780415444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826000283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":17,"alternative-id":["S2211034826000283"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.106992","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoglobulin-G dynamics and relation to antibiotic prescriptions in multiple sclerosis patients treated with rituximab: a real-world cohort","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.106992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106992"}}